Clinical Trial Update: Phase I/II Study of PDR001 in Patients With Advanced Malignancies [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial update for PDR001 in advanced malignancies completed with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Thyroid Cancer
• Melanoma
• Non-small Cell Lung Cancer
• Other Solid Tumors
• Triple-negative Breast Cancer

Drugs mentioned

• PDR001

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Melanoma, Non-small Sell Lung Cancer (NSCLC) | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2021-09-29